Q3 2020 Sales Performance

Respiratory: revenue breakdown 2019 Revenues of £3.1bn (+15% CER) Products Nucala (+33%) £0.8bn (25%) Regions gsk Europe (+29%) £2.3bn (75%) Ellipta portfolio (+10%) Source: GSK Full year 2019 results release - February 2020 All growths at constant exchange rates (CER). Breakdown percentages are approximate US (+6%) £1.7bn (57%) £0.8bn (25%) £0.6bn (18%) International (+31%) 21 21

View entire presentation